REGENXBIO, Inc. Forecast, price target & analysts
REGENXBIO, Inc. Target price 2025 - Analyst rating & recommendation
REGENXBIO, Inc. Classifications & Recommendation:
REGENXBIO, Inc. Price Target
| Target Price | $32.36 |
| Price | $7.27 |
| Potential |
345.17%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target REGENXBIO, Inc. 2026 .
The average REGENXBIO, Inc. target price is $32.36.
This is
345.17%
register free of charge
$52.00
615.27%
register free of charge
$14.00
92.57%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend REGENXBIO, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the REGENXBIO, Inc. stock has an average upside potential 2026 of
345.17%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 90.24 | 86.91 |
| 19.94% | 3.69% | |
| EBITDA Margin | -277.94% | -261.76% |
| 25.33% | 5.82% | |
| Net Margin | -330.42% | -271.09% |
| 15.69% | 17.96% |
10 Analysts have issued a sales forecast REGENXBIO, Inc. 2024 . The average REGENXBIO, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an REGENXBIO, Inc. EBITDA forecast 2024. The average REGENXBIO, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 REGENXBIO, Inc. Analysts have issued a net profit forecast 2024. The average REGENXBIO, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -6.02 | -4.76 |
| 7.38% | 20.93% | |
| P/E | negative | |
| EV/Sales | 2.88 |
3 Analysts have issued a REGENXBIO, Inc. forecast for earnings per share. The average REGENXBIO, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the REGENXBIO, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
REGENXBIO, Inc....
Current REGENXBIO, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs | Buy ➜ Neutral | Downgrade | Feb 11 2025 |
| RBC Capital | Outperform ➜ Outperform | Unchanged | Jan 21 2025 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Jan 15 2025 |
| RBC Capital | Outperform ➜ Outperform | Unchanged | Dec 11 2024 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Nov 21 2024 |
| Chardan Capital | Buy ➜ Buy | Unchanged | Nov 20 2024 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Downgrade
Goldman Sachs: Buy ➜ Neutral
|
Feb 11 2025 |
|
Unchanged
RBC Capital: Outperform ➜ Outperform
|
Jan 21 2025 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Jan 15 2025 |
|
Unchanged
RBC Capital: Outperform ➜ Outperform
|
Dec 11 2024 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Nov 21 2024 |
|
Unchanged
Chardan Capital: Buy ➜ Buy
|
Nov 20 2024 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
